Collaborative Targeted Case Management in Improving Functional Status in Patients With Stage III-IV Cancer

MC1193: Collaborative Care to Preserve Performance in Cancer (COPE)

This randomized clinical trial studies collaborative targeted case management in improving functional status in patients with stage III-IV cancer. Collaborative targeted case management may improve functional mobility, improve quality of life, and reduce pain and health care utilization in patients with advanced cancer

PRIMARY OBJECTIVES:

I. Establish the comparative effectiveness of the Collaborative Care to Preserve Performance in Cancer (COPE) trial arms in preserving functional mobility.

II. To assess the comparative cost-effectiveness and cost-utility of the COPE interventions.

OUTLINE: Patients are randomized to 1 of 3 arms.

ARM I: Patients undergo enhanced usual care comprising telephonic monitoring with monthly status reports provided to their oncology care teams for 6 months.

ARM II: Patients undergo enhanced usual care as in Arm I and participate in an individualized conditioning program delivered telephonically by the Fitness Care Manager (FCM) and adapted, as required, by a local physical therapist for 6 months.

ARM III: Patients undergo enhanced usual care as in Arm I, participate in an individualized conditioning program coordinated by the FCM as in Arm II, and receive optimized pain management through a nurse Pain Care Manager (PCM) for 6 months.

Inclusion Criteria:

• Diagnosis of stage III or stage IV cancer
• Life expectancy > 6 months
• Ambulatory Post Acute Care (APC) score between 53 and 66
• Ability to complete questionnaire(s) by themselves or with assistance
• Provide informed written consent
• Have working phone to communicate with study team
• Fluent in English
• Sufficient auditory acuity
• Intact cognitive status

Exclusion Criteria:

• Patient is within 2 months of a major surgical procedure